MeiraGTx announces Q3 earnings per share of 62 cents, compared to a loss of 55 cents in the previous year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Q3 Financial Performance: The company reported Q3 revenue of $410,000, a significant decrease from $10.9 million last year, while announcing a strategic collaboration with Eli Lilly focused on gene therapy for LCA4, a severe inherited retinopathy.
Gene Therapy Advancements: The AAV-AIPL1 program has shown promising results, with all 11 treated children gaining vision, highlighting the potential of gene therapy for severe genetic conditions when administered early.
Clinical Program Progress: The company is on track with its Phase 2 study of AAV-hAQP1 for radiation-induced xerostomia, expecting to complete enrollment by year-end and potentially file for a BLA in early 2027.
New Initiatives and Collaborations: The company is preparing to initiate a Phase 3 study for AAV-GAD in Parkinson's disease and has optimized its riboswitch program for leptin deficiency, while also developing a treatment for BBS10-associated retinal dystrophy in collaboration with a philanthropic organization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MGTX
Wall Street analysts forecast MGTX stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.650
Low
14.00
Averages
21.50
High
30.00
Current: 10.650
Low
14.00
Averages
21.50
High
30.00
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MeiraGTx Q1 Earnings Miss Expectations
- Earnings Report Shortfall: MeiraGTx reported a Q1 GAAP EPS of -$0.57, missing expectations by $0.18, indicating challenges in profitability that may affect investor confidence moving forward.
- Significant Revenue Decline: The company’s Q1 revenue of $0.29M represents an 85.0% year-over-year decrease, reflecting a substantial drop in product sales or service demand, which could negatively impact future cash flows.
- Increased Cash Reserves: As of March 31, 2026, MeiraGTx's cash, cash equivalents, and restricted cash totaled $73.8M, up from $68.2M as of December 31, 2025, indicating improvements in cash management practices.
- Future Financing Plans: MeiraGTx is eyeing a $100M equity offering following its gene therapy deal with Johnson & Johnson, aimed at strengthening its capital base to support ongoing R&D and commercialization efforts.
See More
MeiraGTx Prices $100M Equity Offering to Acquire Gene Therapy bota-vec
- Equity Offering: MeiraGTx Holdings (MGTX) plans to raise nearly $100 million by pricing an offering of approximately 11.1 million shares at $9.00 each, reflecting the company's confidence in funding the market launch of its gene therapy bota-vec.
- Asset Purchase Agreement: The company has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire bota-vec related to X-linked retinitis pigmentosa, with JNJ receiving $25 million upfront and a milestone payment tied to U.S. approval and sales performance, indicating JNJ's commitment to the product.
- Future Royalties: Under the agreement, beginning mid-2029, JNJ will receive high double-digit royalties based on worldwide net sales of bota-vec, which could provide long-term revenue support for MeiraGTx while underscoring JNJ's confidence in the product's market potential.
- Regulatory Submission Plans: MeiraGTx stated it will immediately file global regulatory submissions for bota-vec approval, with a commercial launch expected in H2 2028, demonstrating the company's strategic positioning and intent to expand in the gene therapy market.
See More
MeiraGTx Acquires bota-vec from J&J for XLRP Treatment
- Asset Purchase Agreement: MeiraGTx has entered into an agreement with Johnson & Johnson to acquire bota-vec for $25 million, significantly enhancing its market position in the treatment of X-linked retinitis pigmentosa (XLRP).
- Global Regulatory Filings: The company intends to immediately pursue global regulatory filings for bota-vec, aiming for a potential launch in 2027, addressing the urgent treatment needs of over 20,000 XLRP patients, which presents substantial market potential.
- Clinical Trial Data Support: The LUMEOS Phase 3 study demonstrated significant improvements in low luminance visual acuity with bota-vec, with many patients reporting real-world benefits, providing strong support for regulatory approval.
- Strategic Development Goals: By reacquiring bota-vec, MeiraGTx not only strengthens its product pipeline but also plans to launch two products targeting severe unmet needs within the next two years, further solidifying its leadership in the gene therapy sector.
See More
MeiraGTx Shares Surge 17% to 52-Week High Ahead of Gene Therapy Data Presentation
- Clinical Trial Data Disclosure: MeiraGTx is set to present early-stage trial data for its AAV-hAQP1 gene therapy on April 16 at 8:00 AM ET, showcasing three-year data from a Phase 1 trial, which could significantly boost investor confidence in the company's future prospects.
- Market Opportunity Analysis: This one-time therapy targets radiation-induced xerostomia, a long-term side effect affecting head and neck cancer patients, indicating a substantial market demand, and successful commercialization could yield significant revenue for the company.
- Clinical Study Context: The open-label AQUAx clinical study evaluated AAV-hAQP1 in patients with grade 2/3 moderate to severe radiation-induced xerostomia who have been cancer-free for at least five years post-radiation therapy, highlighting the therapy's potential efficacy.
- Interactive Session Arrangement: The webcast will include the disclosure of long-term data and a discussion on the drug's commercial opportunities, followed by a Q&A session, enhancing engagement with investors and fostering transparency and trust.
See More
MeiraGTx Presents 3-Year Data from AQUAx Clinical Study
- Clinical Data Presentation: MeiraGTx will present three-year follow-up data from the AAV-hAQP1 treatment for radiation-induced xerostomia during a conference call on April 16, 2026, which is expected to enhance investor confidence in the company's R&D capabilities.
- Study Design Overview: The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose-escalation study primarily assessing the safety of AAV-hAQP1, with efficacy endpoints including patient-reported xerostomia symptoms and changes in parotid gland saliva flow, showcasing the company's innovative potential in gene therapy.
- Patient Follow-Up Plan: Participants will be followed for five years after a one-time administration of AAV-hAQP1, ensuring the long-term validity and reliability of the data, which provides a solid foundation for future clinical applications.
- Commercial Opportunity Discussion: The meeting will include discussions on disease burden, patient experience, and treatment administration, emphasizing MeiraGTx's market potential in addressing radiation-induced xerostomia, which may attract more investor interest in its commercialization prospects.
See More
MeiraGTx Stock Rises After Financial Results Announcement
- Improved Financial Performance: MeiraGTx Holdings plc reported its full-year 2025 financial results, showing a narrower loss of $114.2 million or $1.42 per share, down from $147.8 million or $2.12 per share last year, indicating progress in cost control and operational efficiency.
- FDA Breakthrough Designation: The company received FDA's Breakthrough Designation for its AAV2-hAQP1 treatment targeting Grade 2 and Grade 3 xerostomia caused by radiotherapy, which will expedite product development and potentially enhance market competitiveness, attracting more investor interest.
- Stock Price Movement: Currently, MeiraGTx's stock is trading at $8.04, up 5.51% from the opening price of $7.69, reaching a high of $8.54 during today's session, reflecting optimistic market sentiment regarding the company's prospects.
- Annual Trading Range: Over the past year, MeiraGTx's stock has fluctuated between $4.55 and $9.73, indicating market uncertainty about its business developments, but recent financial improvements may bolster investor confidence.
See More
MeiraGTx Q1 Earnings Miss Expectations
- Earnings Report Shortfall: MeiraGTx reported a Q1 GAAP EPS of -$0.57, missing expectations by $0.18, indicating challenges in profitability that may affect investor confidence moving forward.
- Significant Revenue Decline: The company’s Q1 revenue of $0.29M represents an 85.0% year-over-year decrease, reflecting a substantial drop in product sales or service demand, which could negatively impact future cash flows.
- Increased Cash Reserves: As of March 31, 2026, MeiraGTx's cash, cash equivalents, and restricted cash totaled $73.8M, up from $68.2M as of December 31, 2025, indicating improvements in cash management practices.
- Future Financing Plans: MeiraGTx is eyeing a $100M equity offering following its gene therapy deal with Johnson & Johnson, aimed at strengthening its capital base to support ongoing R&D and commercialization efforts.
See More
MeiraGTx Prices $100M Equity Offering to Acquire Gene Therapy bota-vec
- Equity Offering: MeiraGTx Holdings (MGTX) plans to raise nearly $100 million by pricing an offering of approximately 11.1 million shares at $9.00 each, reflecting the company's confidence in funding the market launch of its gene therapy bota-vec.
- Asset Purchase Agreement: The company has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire bota-vec related to X-linked retinitis pigmentosa, with JNJ receiving $25 million upfront and a milestone payment tied to U.S. approval and sales performance, indicating JNJ's commitment to the product.
- Future Royalties: Under the agreement, beginning mid-2029, JNJ will receive high double-digit royalties based on worldwide net sales of bota-vec, which could provide long-term revenue support for MeiraGTx while underscoring JNJ's confidence in the product's market potential.
- Regulatory Submission Plans: MeiraGTx stated it will immediately file global regulatory submissions for bota-vec approval, with a commercial launch expected in H2 2028, demonstrating the company's strategic positioning and intent to expand in the gene therapy market.
See More
MeiraGTx Acquires bota-vec from J&J for XLRP Treatment
- Asset Purchase Agreement: MeiraGTx has entered into an agreement with Johnson & Johnson to acquire bota-vec for $25 million, significantly enhancing its market position in the treatment of X-linked retinitis pigmentosa (XLRP).
- Global Regulatory Filings: The company intends to immediately pursue global regulatory filings for bota-vec, aiming for a potential launch in 2027, addressing the urgent treatment needs of over 20,000 XLRP patients, which presents substantial market potential.
- Clinical Trial Data Support: The LUMEOS Phase 3 study demonstrated significant improvements in low luminance visual acuity with bota-vec, with many patients reporting real-world benefits, providing strong support for regulatory approval.
- Strategic Development Goals: By reacquiring bota-vec, MeiraGTx not only strengthens its product pipeline but also plans to launch two products targeting severe unmet needs within the next two years, further solidifying its leadership in the gene therapy sector.
See More
MeiraGTx Shares Surge 17% to 52-Week High Ahead of Gene Therapy Data Presentation
- Clinical Trial Data Disclosure: MeiraGTx is set to present early-stage trial data for its AAV-hAQP1 gene therapy on April 16 at 8:00 AM ET, showcasing three-year data from a Phase 1 trial, which could significantly boost investor confidence in the company's future prospects.
- Market Opportunity Analysis: This one-time therapy targets radiation-induced xerostomia, a long-term side effect affecting head and neck cancer patients, indicating a substantial market demand, and successful commercialization could yield significant revenue for the company.
- Clinical Study Context: The open-label AQUAx clinical study evaluated AAV-hAQP1 in patients with grade 2/3 moderate to severe radiation-induced xerostomia who have been cancer-free for at least five years post-radiation therapy, highlighting the therapy's potential efficacy.
- Interactive Session Arrangement: The webcast will include the disclosure of long-term data and a discussion on the drug's commercial opportunities, followed by a Q&A session, enhancing engagement with investors and fostering transparency and trust.
See More
MeiraGTx Presents 3-Year Data from AQUAx Clinical Study
- Clinical Data Presentation: MeiraGTx will present three-year follow-up data from the AAV-hAQP1 treatment for radiation-induced xerostomia during a conference call on April 16, 2026, which is expected to enhance investor confidence in the company's R&D capabilities.
- Study Design Overview: The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose-escalation study primarily assessing the safety of AAV-hAQP1, with efficacy endpoints including patient-reported xerostomia symptoms and changes in parotid gland saliva flow, showcasing the company's innovative potential in gene therapy.
- Patient Follow-Up Plan: Participants will be followed for five years after a one-time administration of AAV-hAQP1, ensuring the long-term validity and reliability of the data, which provides a solid foundation for future clinical applications.
- Commercial Opportunity Discussion: The meeting will include discussions on disease burden, patient experience, and treatment administration, emphasizing MeiraGTx's market potential in addressing radiation-induced xerostomia, which may attract more investor interest in its commercialization prospects.
See More
MeiraGTx Stock Rises After Financial Results Announcement
- Improved Financial Performance: MeiraGTx Holdings plc reported its full-year 2025 financial results, showing a narrower loss of $114.2 million or $1.42 per share, down from $147.8 million or $2.12 per share last year, indicating progress in cost control and operational efficiency.
- FDA Breakthrough Designation: The company received FDA's Breakthrough Designation for its AAV2-hAQP1 treatment targeting Grade 2 and Grade 3 xerostomia caused by radiotherapy, which will expedite product development and potentially enhance market competitiveness, attracting more investor interest.
- Stock Price Movement: Currently, MeiraGTx's stock is trading at $8.04, up 5.51% from the opening price of $7.69, reaching a high of $8.54 during today's session, reflecting optimistic market sentiment regarding the company's prospects.
- Annual Trading Range: Over the past year, MeiraGTx's stock has fluctuated between $4.55 and $9.73, indicating market uncertainty about its business developments, but recent financial improvements may bolster investor confidence.
See More
